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Available online 3 December 2012Abstract Induced-pluripotent stem cells (iPSCs) are a potential alternative cell source in regenerative medicine, which
includes the use of differentiated iPSCs for cell therapies to treat coronary artery and/or peripheral arterial diseases.
Late-outgrowth endothelial progenitor cells (late-EPCs) are a unique primary cell present in peripheral blood that exhibit high
proliferative capacity, are being used in a wide variety of clinical trials, and have the ability to differentiate into mature
endothelial cells. The objective of this study was to reprogram peripheral blood-derived late-EPCs to a pluripotent state under
feeder-free and defined culture conditions. Late-EPCs that were retrovirally transduced with OCT4, SOX2, KLF4, c-MYC, and
iPSC colonies were derived in feeder-free and defined media conditions. EPC-iPSCs expressed pluripotent markers, were
capable of differentiating to cells from all three germ-layers, and retained a normal karyotype. Transcriptome analyses
demonstrated that EPC-iPSCs exhibit a global gene expression profile similar to human embryonic stem cells (hESCs). We have
generated iPSCs from late-EPCs under feeder-free conditions. Thus, peripheral blood-derived late-outgrowth EPCs represent
an alternative cell source for generating iPSCs.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.Abbreviations: ALP, alkaline phosphatase; EBs, embryoid bodies; GMP, good manufacturing practice; H&E, hematoxylin and eosin; hESC,
human embryonic stem cells; iPSC, induced-pluripotent stem cells; Late-EPC, late-outgrowth endothelial progenitor cells; SMA, smooth
muscle actin.
⁎ Corresponding author at: Sprott Centre for Stem Cell Research, Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa,
Canada. Fax: +1 613 739 6294.
E-mail address: wstanford@ohri.ca (W.L. Stanford).
1 Current Address: STEMCELL Technologies, Inc., Vancouver, BC, Canada.
1873-5061
http://dx.doi.org/10.1016/j.scr.2012.11.006
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.
196 W.Y. Chang et al.Introduction
Cell therapies hold great promise for the treatment of
numerous human diseases and disorders. For example,
atherosclerotic vascular disease is a major cause of heart
failure and contributes importantly to the growing burden of
chronic disease. The use of stem cells to promote cardiac
repair or restore perfusion to tissues represents an important
strategy to avoid the deleterious consequences of occlusive
vascular disease. In preclinical studies, the administration of
adult stem and progenitor cells has been shown to improve
cardiac function post acute myocardial infarction and restore
perfusion to the ischemic hindlimb; however, their efficacy in
clinical trials has been at best modest (Lasala and Minguell,
2011). These include endothelial progenitor cells (EPCs) that
can be isolated from bone marrow or circulating mononuclear
cells by surface marker selection of culture specification. The
latter can be classified into early outgrowth EPCs (or
circulating angiogenic cells) that appear within 3 days of
culture, and late outgrowth EPCs (or blood outgrowth
endothelial cells) that only appear after 2 weeks and then
rapidly overgrow the early growth cells. Unlike the early
cells, late-outgrowth EPCs are highly differentiated to an
endothelial phenotype and exhibit high growth and colony
forming potential (Lavoie and Stewart, 2012).
The recent discovery of iPSCs provides a potential alterna-
tive cell source for cell therapies and regenerative medicine
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007).
However, a more immediate impact of iPSCs is its application
to modeling human diseases and disorders (Chang et al., 2012;
Grskovic et al., 2011); for example, iPSCs derived from patients
harboring genetic perturbations that result in premature
atherosclerosis can be used to screen for novel anti-
atherosclerosis therapies. Since the initial demonstration of
somatic reprogramming to a pluripotent state by the exogenous
expression of Oct4, Sox2, Klf4, and c-Myc in dermal fibroblasts
(Takahashi et al., 2007), numerous additional somatic cell types
have been reprogrammed into iPSCs including neural pro-
genitors (Eminli et al., 2008), B-cells (Choi et al., 2011), T-cells
(Brown et al., 2010; Loh et al., 2010; Seki et al., 2010),
adipocytes (Sun et al., 2009), and endothelial cells (Ho et al.,
2010). Although some of these cell types can be reprogrammed
with high efficiency, many are not readily accessible. Blood
cells are perhaps the most easily accessible but lymphocytes,
the targets of most established blood-derived iPSCs, have
limited proliferative capacity preventing banking of sufficient
primary cells for future reprogramming with improved technol-
ogies and use in genomic and proteomic assays. Alternatively,
late-outgrowth EPCs (late-EPCs) can also be isolated from
peripheral blood, in fact, from as little as 3–5 ml of blood
(Martin-Ramirez et al., 2012). These cells exhibit high prolifer-
ative capacity; for example, 1019 cells can be generated from a
starting 100 ml culture within 2 months (Lin et al., 2000).
Interestingly, peripheral blood late-EPC progenitor frequencies
are often altered in disease states. However, in general,
pathogenic states increase the frequency of circulating late-
EPC progenitors (Jodon de Villeroche et al., 2010; Thill et al.,
2008) making them generally accessible from controls and
patient’s blood samples of 20–30 ml. In this report, we
isolate late-EPCs from peripheral blood and reprogram
these cells into iPSCs under feeder-free and defined media
conditions.Materials and methods
Derivation and cell culture of late-outgrowth EPCs
Three healthy donors were used to derive late-EPCs with
informed consent. Leukapheresis product (lines 106 and 124)
was isolated from patients using a Cobe Spectra 7.0 Apheresis
System. Approximately 200 ml of mononuclear cell volume
was collected from each patient. To derive late-EPCs from
leukapheresis product, 40 ml from each sample was diluted
with 3 volumes of Dulbecco's phosphate-buffered saline (DPBS)
and centrifuged in a Ficoll-Paque PLUS (GE Healthcare)
density gradient according to the manufacturer's instructions,
whereas the PB1 late-EPC line was derived from 30 ml of
whole peripheral blood. Mononuclear cells (MNCs) were
fractionated from other components of peripheral blood by
centrifugation on Ficoll-Paque PLUS. MNCs can be used
immediately for late-EPC isolation or frozen in 10% DMSO
without affecting isolation of late-EPCs or affecting the
capacity of the late-EPCs to be reprogrammed. MNCs were
then cultured on fibronectin-coated plates (Roche Applied
Science) in Endothelial Growth Medium-2MV (CC-3202, Lonza)
(basal endothelial media-2 (EBM), 20% human serum, VEGF,
bFGF, IGF, EGF, gentamicin, ascorbic acid, and hydrocorti-
sone). Late-outgrowth EPCs (late-EPCs) formed approximately
18 days after culturing in EGM-2MV. Late-EPCs exhibited a
high proliferative capacity and had a cobblestone appearance.
All experiments were performed with passage 7 or earlier
late-EPCs. To passage late-EPC, cells were washed with PBS
and trypsinized with 0.05% Trypsin-EDTA (25300120, Life
Technologies).In vitro endothelial cell tube formation assay
Endothelial tube formation assays were performed in 96-well
plates coated with Matrigel (354230, Becton Dickinson), a
reconstituted basement membrane matrix. Approximately,
2×104 late-EPCs were seeded into each well with 200 μL
EGM-2MV+20% human serum media. Capillary-like networks
were then monitored and imaged 16 h later.Reagents and cell culture of EPC-iPSCs
EPC-iPSCs were maintained on matrigel (BD Biosciences) in
E8 media (DMEM/F12, L-ascorbic acid-2-phosphate magne-
sium) (Sigma), sodium selenium (14 μg/l, Sigma), FGF2
(100 μg/l, Life Technologies), insulin (19.4 mg/l, Roche),
NaHCO3 (543 mg/l, Sigma), transferrin (10.7 mg/l, Sigma),
and TGFβ1 (2 μg/l, Life Technologies) (Chen et al., 2011)
under hypoxic conditions (10% CO2, 5% O2). EPC-iPS colonies
were initially passaged mechanically and then enzymatical-
ly with collagenase (#07923 or #07909, Stem Cell Technol-
ogies). Enzymatic passaging was performed by first washing
the cells with 2 ml of PBS and then 1 ml of collagenase was
added and the iPSCs were incubated at 37 °C for 10 min.
The collagenase solution was removed and cells were rinsed
once with DMEM/F12. Colonies were scraped with a cell
scraper, dissociated to smaller clumps by resuspending E8
medium.
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late-outgrowth EPCs
Retrovirus was generated using constructs pMXs-hOCT4,
pMXs-hSOX2, pMXs-hKLF4, and pMXs-hc-MYC (Addgene) as
described previously (Hotta et al., 2009a, 2009b). To generate
VSV-G pseudotyped retrovirus, Plat-GP cells were transfected
overnight with 15 μg of each Yamanaka expression vector and
5 μg of pVSV-G using Lipofectamine 2000 according to the
manufacturer. The next day, the medium was replaced with
10 ml of Endothelial Growth Medium-2MV to collect viral
particles. Two days post-transfection, retrovirus was collect-
ed and filtered through a 0.45 μm filter. Transduction of
5×104 late-EPCs was performed by the addition of protamine
sulfate to a final concentration of 4 μg/ml to a retroviral
cocktail containing 500 μl of each transcription factor.
Late-EPCs were transduced overnight with the retroviral
cocktail. After transduction, late-EPCs were maintained in
complete EGM-2MV medium for 7–14 days, then trypsinized
and replated onto matrigel coated plates. Unlike fibroblast
reprogramming, in which we transfer on day 7 to hESC
conditions (E8 media), we found that reprogramming efficien-
cies were enhanced for EPC reprogramming by growing in
EGM-2MV until colonies resembling hESCs in morphology
emerged. These were then mechanically picked and replated
onto matrigel. These iPSCs were mechanically dissociated for
a few passages and then adapted to collagenase IV passaging.
To determine reprogramming efficiency, the number of
ES-like colonies was counted based onmorphology and divided
by the number of starting cells that were transduced with the
retroviral cocktail of Oct4, Sox2, Klf4, and c-Myc.
Microarray analyses
Total RNA was isolated with the Nucleospin RNA II kit
(Macherey-Nagel) according to the manufacturer and micro-
array analyses were performed at the Stem Core Facility
(Ottawa Hospital Research Institute) on the Affymetrix
Human Gene 1.0 ST arrays. Data analyses were performed
as previously described (Walker et al., 2010). The microar-
ray data has been deposited into the GEO database with the
accession number GSE42947.
Embryoid body and teratoma assays
Embryoid bodies (EBs) were formed by treating EPC-iPSCs with
collagenase IV (STEMCELL Technologies) for 30–40 min, scraped
and transferred to ultra-low attachment dishes (#3471, Costar).
EBs were cultured for 7 days in suspension in E8 medium
(without bFGF, and supplemented with 10% FBS) and out-
growths were formed by plating the EBs onto gelatin-coated
plates. Teratomas were generated by injecting 1.5 million cells
intramuscularly; tumors were removed approximately 8 weeks
later, sectioned and stained with H&E.
Flow cytometry analysis
Flow cytometry analysis was performed as previously described
(Ormiston et al., 2010); briefly, late-EPCs were trypsinized
with TrypLE (Invitrogen), washed, and then incubated with 10%
mouse serum for 30 min on ice and stained with the following:
α-CD14–PE (#555398), α-CD45–PE (#555483), α-CD31–PE(#555446) and α-KDR–PE (#560494) (all flow cytometry anti-
bodies were purchased from BD Biosciences). Isotype-matched
antibodies were used as negative controls. Cells were analyzed
on a Quanta SC flow cytometer (Beckman Coulter).
Immunofluorescence analysis
Immunofluorescence analyses were performed a previously
described (Chang et al., 2004). Briefly, cells were fixed in 3.7%
formaldehyde for 20 min at room temperature and washed
with PBS. Samples were then permeabilized with 0.1 Triton
X-100 for 20 min and blocked for 1 h with 3% skim milk in PBS,
and primary antibodies were incubated for 2 h at room
temperature or overnight at 4 °C. Primary antibodies for
pluripotency markers were purchased from Millipore, Tra-1-60
(MAB4360), Tra-1-81 (MAB4381), and SSEA4 (MAB4304) and
were used at 1:200, 1:200, and 1:500 dilutions, respectively.
Differentiation markers used were βIII-tubulin (MAB1637,
Millipore), smooth muscle actin (CBL171, Millipore), and
Gata4 (G1610, Santa Cruz) at a dilution of 1:500.
Results
Reprogrammed late-outgrowth EPCs under
feeder-free conditions are pluripotent
Late-EPCs were isolated from peripheral blood by apheresis or
from 30 ml whole blood, characterized and exhibited their
typical cobblestone morphology (Fig. 1B and Supplemental Fig.
1A) similar to endothelial cells and readily formed a
capillary-like network when cultured on Matrigel (Supplemen-
tal Fig. 1B). Cell surface marker examination demonstrated
that these cells were CD31+/VEGFR2+/CD14−/CD45−, charac-
teristic of late-EPCs (Supplemental Fig. 1C) (Ormiston et al.,
2010). To reprogram late-EPCs, cells were retrovirally trans-
duced with OCT4, SOX2, KLF4, and c-MYC. After 7–14 days,
cells were replated onmatrigel in hESC E8 definedmedia (Chen
et al., 2011) (schematic of reprogramming, Fig. 1A). Colonies
exhibiting morphology similar to hESCs arose between 21 and
30 days (Fig. 1C), consistent with the time course for
reprogramming of fibroblasts. Three late-EPC lines (106, 124,
and PB1) were reprogrammed exhibiting a reprogramming
efficiency varying between 0.006% and 0.7% depending on the
line (Table 1), which is consistent with the range of
reprogramming efficiency observed using a variety of dermal
fibroblasts in our laboratory aswell as other published cell types
(Ho et al., 2010; Hotta et al., 2009a; Sun et al., 2009; Takahashi
et al., 2007). ESC-like colonies were then picked and expanded
under feeder-free conditions. To assay their pluripotency
potential, we examined several iPSC clones generated from
each late-EPC line for the expression of alkaline phosphatase
(ALP), SSEA4, TRA-1-81, and TRA-1-60 (see Fig. 1D–K and
Supplemental Fig. 2 for examples of 106 and PB1 lines).
Further, karyotype analyses demonstrated no gross chromo-
somal anomalies in our EPC-iPSC lines (Fig. 1L).
To assess whether the global gene expression patterns
were reverted to an ESC-like state, we performed global
transcriptomemicroarray analyses of four 106-iPSC clones and
compared their signature to the parental late-EPC and H9
hESC lines. Shown in Fig. 2A are the global gene expression
scatter plot analyses of clones 106-iPS1C and 106-iPSC1D
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Figure 1 EPC-derived iPSCs express pluripotent markers, and retain normal karyotype. (A) Schematic of the feeder-independent
method for reprogramming late-EPCs to iPSCs. Approximately 4 weeks after retroviral transduction of (B) late-EPCs, colonies
resembling (C) ES-like morphology appeared. These colonies expressed pluripotent markers SSEA4, TRA1-81, TRA1-60, and ALP.
Two clones are shown from the 106 donor, 106-iPS1C (D–G) and 106-iPS1D (H–K), scale bar=200 μm. (L) EPC-iPSC exhibit normal
karyotype.
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Table 1 Reprogramming efficiency of late-outgrowth
endothelial progenitor cells transduced with retrovirus
expressing Oct4, Sox2, Klf4, and c-Myc.
L-EPC line Number
of cells
transduced
Number of ES-like
colonies based on
morphology
Reprogramming
efficiency (%)
106 50000 389 0.7
124 50000 3 0.006
PB1 50000 10 0.02
199Feeder-free iPSCs from late-outgrowth EPCscompared to H9 hESCs and the parental late-EPC line. Pearson
coefficient of all the 106-iPSC clones shows high correlation
greater than 0.97 with the H9 hESC line, whereas the
correlation with parental EPCs was less than 0.90. While we
found that SOX2 and OCT4 (POU5F1) expression in EPC-iPSC
lines essentially equivalent to H9 hESCs, c-MYC and KLF4
expression were slightly increased, although their expression
was much decreased compared to the 106 parental EPC line
(Fig. 2). This may be due to incomplete reprogramming, as
RNA was isolated from very early passage cells for microarray
analysis. Analysis of specific probes in our microarray data
showed that genes involved in pluripotency are upregulated in
EPC-iPSCs such as NANOG, hTERT, and SALL4, whereas genes
involved in endothelial function including GATA2, NOS3, TEK,
and EBPH4 are down-regulated compared to the parental
late-EPCs (heatmap in Fig. 2B). In addition, genes associated
with hematopoietic function were not significantly expressed
in late-EPCs. Interestingly, our transcriptome analysis of the
106 parental line showed that these cells exhibited high levels
of KLF4 and c-MYC. Therefore, we subsequently attempted to
reprogram the 106 line with 2-factors (OCT4 and SOX2) or
3-factors (OCT4, SOX2, and KLF4) and (OCT4, SOX2, and
c-MYC). Transduction of the 106 EPC line with 2 or 3-factors
did not yield any ES-like or ALP-positive colonies compared to
4-factor transductions (data not shown).
To determine whether EPC-iPSCs have the capacity to
differentiate to cells and tissues of all three germ-layers, we
performed both in vitro and in vivo differentiation assays.
Embryoid bodies (EBs) (Fig. 3A and Supplemental Fig. 2) were
generated from 106-iPSCs and PB1-iPSCs for 7 days and cell
outgrowths were formed over 3 days. Outgrowths were then
stained for markers of the three germ-layers, βIII-tubulin
(ectoderm), smooth muscle actin (SMA) (mesoderm), and
GATA6 (endoderm). We identified cells in our EB cultures that
were positive for thesemarkers fromeach EPC-iPSC line (Fig. 3B
and Supplemental Fig. 2I, for example). To examine the in vivo
differentiation capacity of EPC-iPSCs, we performed teratoma
assays. Teratomas containing tissues from all three germ layers,
such as pigmented epithelium (ectoderm), cartilage (meso-
derm), and columnar epithelium reminiscent of gut or lung
epithelium (endoderm), were generated from two 106-iPSC
clones (Fig. 3C). Taken together, our differentiation assays
demonstrate that EPC-iPSCs are pluripotent.Discussion
Currently, a number of cell types such as EPCs, bone marrow
mononuclear cells, and mesenchymal stromal cells are beingtested in clinical trials for their efficacy in treating
cardiovascular diseases (O'Neill et al., 2012). Although
there appears to be some benefit with adult cell therapy,
this appears to be modest, and dependent primarily on
paracrine mechanisms (Lasala and Minguell, 2011). Thus, the
initial hypothesis that these cells would robustly differenti-
ate into cardiac and vascular cells and directly regenerate
damaged tissue has largely been unfulfilled. Human ESCs,
and now iPSCs, offer potential alternative cell sources for
cell therapy with much greater potential for differentiation
and tissue regeneration. As well, derivation of iPSCs from
patients with disease represents a valuable tool to better
define underlying disease etiology and to screen for new
drug therapies. However, the need for biopsy samples to
derive patient-specific iPSCs is a major limitation, particu-
larly the access to biopsies from relatives of the patients to
act as genetic controls. Thus, the ability to derive iPSCs from
blood enables the wider application of this technology and
study of a broader range of diseases.
Collectively, our data shows that EPC-iPSCs are pluripotent.
Further, we have reprogrammed late-EPCs under feeder-free
and defined conditions, which should facilitate the progress of
ultimately using EPC-derived iPSCs in a clinical setting.
However, before this can be achieved, reprogramming of
late-EPCs using non-integrating methods would be necessary.
In the course of our study, we attempted to reprogram late-
EPCs using several non-integrating strategies such Sendai Virus
(Macarthur et al., 2012) and episomal vectors (Okita et al.,
2011). Using these reprogrammingmethods wewere not able to
achieve successful reprogramming (data not shown). In fact,
Sendai virus mediated reprogramming killed the late-EPCs,
while generating control iPSCs. Despite generating adult dermal
fibroblast-derived iPSCs using episomal reprogramming vectors,
late-EPCs transfected with these vectors did not proliferate
well after switching to the hESC medium at different times
post-transfection, suggesting expression of the reprogramming
factors was not high enough to induce reprogramming. Thus,
further optimization including the use of small molecules or the
use of alternate reprogramming methodologies such as mRNA is
required for successful non-integrative reprogramming of
late-EPCs. Nonetheless, our study is a step forward in utilizing
peripheral blood-derived late-EPCs as a cell source to derive
feeder-free iPSCs in defined conditions. Late-EPCs represent an
ideal cell source for reprogramming because of their accessi-
bility from peripheral blood, their high proliferative capacity,
and homogeneous population that can be frozen and thawed
(Lin et al., 2011) for future genomic and proteomic analysis.
Furthermore, unlike lymphoid lineages, L-EPCs do not undergo
V(D)J recombination; therefore iPSCs derived from L-EPCwould
closer reflect other cell types from the donor which can
eventually be applied to understanding diseases/disorders.
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